Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD-Reference-Cited by-同舟云学术

Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD

Published:2013-09 Issue:3 Volume:144 Page:758-765
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

White William B.,Cooke Glen E.,Kowey Peter R.,Calverley Peter M.A.,Bredenbröker Dirk,Goehring Udo-Michael,Zhu Haiyuan,Lakkis Hassan,Mosberg Hans,Rowe Paul,Rabe Klaus F.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference31 articles.

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary;Rabe;Am J Respir Crit Care Med,2007

2. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care;Feary;Thorax,2010

3. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT);Hawkins;Eur J Heart Fail,2009

4. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes;Salisbury;Am J Cardiol,2007

5. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality;Burgel;PLoS ONE,2012

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injury;Expert Opinion on Therapeutic Targets;2024-06-19

2. Cardiac comorbidity and COPD: chance or consequence?;COPD in the 21st Century;2024-03-01

3. PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets;International Journal of Molecular Sciences;2023-11-30

4. Novel pharmacological approaches in abdominal aortic aneurysm;Clinical Science;2023-08

5. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO);The Lancet Regional Health - Europe;2023-07